Sanofi Sees Booster Role For Covid Vaccine After Solid But Underwhelming Results

Lower Efficacy In Older Adults

Once expected to play a key role in beating COVID-19, Sanofi and GSK now see their vaccine as most likely to be used as a booster.

Sanofi_Berlin
A lower immune response in older adults was the problem which delayed the vaccine's development, but may not have been entirely resolved.

Sanofi has revealed solid but underwhelming topline Phase II results from its delayed COVID-19 vaccine, which showed the neutralizing antibody levels produced were ‘comparable’ to that produced by a natural infection.

The company has not yet published the full data either in a pre-print publication or academic journal, but the results...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip